Trastuzumab in Early-Stage Breast Cancer: The Question of Treatment Timing

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.26, Iss.10, 2008-01, pp. : 807-809

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic Evaluation and Decision Making: Reimbursing Trastuzumab in Early-Stage Breast Cancer

By Simoens Steven

PharmacoEconomics, Vol. 25, Iss. 3, 2007-01 ,pp. : 181-185

Adis International

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

By Plosker Greg L. Keam Susan J.

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 449-475

Adis International

Access to resources Recommend Favorite

Quality-of-Life Considerations in the Treatment of Early-Stage Breast Cancer in the Elderly

By Reimer Toralf Gerber Bernd

Drugs & Aging, Vol. 27, Iss. 10, 2010-10 ,pp. : 791-800

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model

By Millar J. Alasdair Millward Michael J.

PharmacoEconomics, Vol. 25, Iss. 5, 2007-01 ,pp. : 429-442

Adis International

Access to resources Recommend Favorite

In defence of trastuzumab for early breast cancer

Inpharma, Vol. 1, Iss. 1521, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite